Back

Weekly Journal Scan: SELECT renoprotective effects of semaglutide in non-diabetic, obese patients with cardiovascular disease

European Heart Journal

4 September 2024
Organised by: Logo
Read full article
ESC Journals

Contributors

Rocco Vergallo
Rocco Vergallo

Author

Massimo Volpe
Massimo Volpe

Author

Sapienza University of Rome Rome , Italy

You may be interested in
thumbnail
Webinar
GLP-1 RAs and HFpEF : what do we know from large RCTs about GLP-1 RAs and their effects on HFpEF?
24 November 2025
thumbnail
Congress Presentation
Comparison of sodium-glucose cotransporter-2 (SGLT2) inhibitors to reduce cardiovascular and renal outcomes: a network meta-analysis of randomized controlled trials
28 August 2023
thumbnail
Congress Presentation
Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes
1 September 2025
thumbnail
ESC TV Today
Episode 3: Artificial sweeteners and cardiovascular risk - Optimal management of angina
24 October 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources